Laurel Habel to Biomarkers, Tumor
This is a "connection" page, showing publications Laurel Habel has written about Biomarkers, Tumor.
Connection Strength
1.973
-
Reply to L. Cabel et al. J Clin Oncol. 2015 Jan 20; 33(3):292-3.
Score: 0.462
-
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10; 32(20):2151-8.
Score: 0.445
-
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013 Mar 14; 15(2):R24.
Score: 0.409
-
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. Nat Commun. 2017 01 31; 8:14248.
Score: 0.134
-
Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care. 2016 05 01; 22(5):e153-60.
Score: 0.127
-
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
Score: 0.109
-
Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
Score: 0.109
-
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010 Oct 01; 28(28):4300-6.
Score: 0.085
-
Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021 02 12; 12(1):970.
Score: 0.044
-
A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov. 2015 Aug; 5(8):878-91.
Score: 0.030
-
Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 Apr 16; 100(8):597-8; author reply 599.
Score: 0.018